Параноїдна шизофренія, поєднана з вживанням канабіноїдів: епідеміологічний, етіопатогенетичний та клінічний аспекти (огляд літератури)
Анотація
У дослідженнях останніх років відзначається зростання зацікавленості вітчизняних та іноземних дослідників до коморбідної патології – поєднання психіатричного захворювання з вживанням психоактивних речовин. Метою цього огляду було на підставі аналізу літературних джерел вивчити вплив вживання канабіноїдів на шизофренічний процес та визначити, які аспекти параноїдної шизофренії, поєднаної з вживанням канабіноїдів, досліджені недостатньо, висвітлені не в повному обсязі. Аналіз літературних джерел свідчить про те, що проблема коморбідності параноїдної форми шизофренії та вживання канабіноїдів (як із залежністю від цих речовин, так і без неї) залишається далекою від вирішення.
Завантаження
Посилання
Harchenko Je. M. [ta in.] Komorbidnist’ endogennyh psyhichnyh rozladiv iz zalezhnistju vid psyhoaktyvnyh rechovyn (stan problemy) [Komorbidnist endogenous mental disorders with substance dependence (state problem)]. Arhiv psyhiatrii’, 2009, no. 3, pp. 53-55. (In Ukr.)
Afanas’eva A. V. Osobennosti upotreblenija psihoaktivnyh veshhestv bol’nymi shizofreniej i ego vlijanie na techenie shizofrenicheskogo processa (Obzor literatury) [Features substance use patients with schizophrenia and its impact on the course of schizophrenia (Review of literature)]. Ukrai’ns’kyj visnyk psyhonevrologii’, 2011, no. 3, pp. 82-85. (In Russ.)
Arseneault L. [et al.] Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British medical journal, 2002, no. 325, pp. 1212-1213.
Di Forti M., Murray R. M. Cannabis consumption and risk of developing schizophrenia: myth or reality? Social psychiatry and psychiatric epidemiology, 2005, no. 14, pp. 184-187.
Compton M. T. [et al.] Association of pre-onset cannabis, alcohol, and tobacco use with the age at onset of prodrome and age at onset of psychosis in first-episode patients. American journal of psychiatry, 2009, no. 11, pp. 1251-1257.
Compton M. T., Ramsay C. E. The impact of pre-onset cannabis use on age at onset of prodromal and psychotic symptoms. Primary рsychiatry, 2009, no. 16, pp. 35-43.
Semple D. M. [et al.] Cannabis as a risk factor for psychosis: systematic review. Journal of psychopharmacology, 2005, no. 2, pp. 187-194.
Subbotin O. Debyut shizofrenii kak sledstvie potrebleniya kannabisa v podrostkovom vozraste [The debut of schizophrenia as a result of consumption of cannabis in teens]. Vestnik Ivanovskoy meditsinskoy akademii, 2007, no. 1-2, pp. 84-88. (In Russ.)
Ferdinand R. F. [et al.] Cannabis – psychosis pathway independent of other types of psychopathology. Schizophrenia research, 2005, no. 2-3, pp. 289-295.
Dudin I. I. Premorbidnye sotsial’no-biologiche skie i lichnostno-psikhologicheskie faktory, predisponiruyushchie formirovaniyu zavisimosti ot kannabinoidov u bol’nykh s sochetannymi psikhicheskimi rasstroystvami [Premorbid social and biological and personal-psycho-logical factors predisposing the formation depending on cannabinoids in patients with concomitant mental disorders]. Dal’nevostochnyy meditsinskiy zhurnal, 2008, no. 3, pp. 84-86. (In Russ.)
van Kharen N. E. [i dr.] Shizofreniya kak progres siruyushchee zabolevanie golovnogo mozga [Schi zophrenia as a progressive disease of the brain]. Sotsial’naya i klinicheskaya psikhiatriya, 2008, no. 2, pp. 26-35. (In Russ.)
Zammit S. [et al.] Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts 1969: historical cohort study. British medical journal, 2002, no. 35, pp. 1199-1201.
Psikhicheskie posledstviya upotrebleniya kannabionoidov [Mental consequences of the use of cannabinoids]. Voprosy narkologii, 2002, no. 5, pp. 71 -72. (In Russ.)
Bokhan N. A. [i dr.] Komorbidnye addiktivnye rasstroystva u bol’nykh shizofreniey [Comorbid addictive disorders in patients with schizophrenia]. Narkologiya, 2002, no. 6, pp. 24-30. (In Russ.)
Maddock C., Babbs М. Intervention for cannabis misuse. Advances in psychiatric treatment, 2006, no. 12, pp. 432-439.
Arseneault L. [et al.]Causal association between cannabis and psychosis: examination of the evidence. British medical journal, 2004, no. 184, pp. 110-117.
Bazarbaeva L. E. Faktory, vliyayushchie na kliniku shizofrenii, oslozhnennoy narkomaniey (po materialam sudebno-psikhiatricheskikh ekspertiz) [Factors affecting the clinic schizophrenia complicated by drug addiction (based on forensic psychiatric examinations)]. Sibirskiy vestnik psikhiatrii i narkologii, 2009, no. 2, pp. 124-125. (In Russ.)
Henquet C. [et al.] Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British medical journal, 2005, no. 330, pp. 11-16.
Reinarman C. [et al.] Endocannabinoids in schizophrenia – do they play role? European psychiatry, 2004, no. 19, p. 79.
Fergusson D. M. [et al.] Cannabis dependence and psychotic symptoms in young people. Psychological medicine, 2003, no. 33, pp. 15-21.
Primenenie psikhoaktivnykh veshchestv pri shizofrenii. Marikhuana pri shizofrenii [The use of psychoactive substances in schizophrenia. Marijuana in schizophrenia]. Meditsinskiy portal Meduinver. Available at: http://meduniver.com/Medical/Psixology/154.html (14.12.2013). (In Russ.)
Blednykh M. A. Upotreblenie psikhoaktivnykh sredstv i priverzhennost’ k terapii u patsientov s vpervye diagnostirovannoy paranoidnoy shizofreniey [The use of psychoactive drugs and adherence to therapy in patients with newly diagnosed paranoid schizophrenia]. Nevrologicheskiy vestnik, 2012, no. 2, pp. 92-94. (In Russ.)
Kumra S. Schizophrenia and cannabis use. Minnesota medicine, 2007, no. 1, pp. 36-38.
Green A. I. [et al.] First-episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia research, 2004, no. 2-3, pp. 125-135.
Hambrecht M., Hafner H. Substance abuse and the onset of schizophrenia. Biological Psychiatry, 1996, no. 40, pp. 1155-1163.
Linszen D. [et al.] Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of general psychiatry, 1994, no. 51, pp. 273- 279.
Veen N. D. [et al.] Cannabis use and age at onset of schizophrenia. American journal of psychiatry, 2004, no. 3, pp. 501-506.
Ahmed A. O. [et al.] Handbook of schizophrenia spectrum disorders. Volume III [ed. by M. S. Ritsner]. Springer, Science, 2011, 462 p.
Smit F. [et al.] Cannabis use and the risk of later schizophrenia: a review. Addiction, 2004, no. 4, pp. 425-430.
Hall W. [et al.] Cannabis use and psychotic disorders: an update. Drug and alcohol review, 2004, no. 4, pp. 433-443.
Dvorjak S. V. [et al.] Likuvannja opioi’dnoi’ zalezhnosti agonistamy opioi’div [Treatment of opioid dependence opioid agonists]. Kiev, 2012, 283 p. (In Ukr.)
Weiser M., Noy S. Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues in Clinical Neuroscience, 2005, no. 1, pp. 81-85.
Henquet C. [et al.] The environment and schizophrenia: the role of cannabis use. Schizophrenia bulletin, 2005, no. 3, pp. 608-612.
Cannabis use and brain structural alterations in first episode schizophrenia – a region of interest, voxel based morphometric study / S. S. Bangalore [et al.] // Schizophrenia research, 2008, no. 99. – Р. 1-6.
Veling W. [et al.] Cannabis use and genetic predisposition for schizophrenia: A casecontrol study. Psychological medicine, 2008, no. 38, pp. 1251-1256.
Trailin A. V., Levada O. A. Genetika i epigenetika shizofrenii [Genetics and epigenetics of schizophrenia]. NeyroNews, 2012, no. 6, pp. 18-28. (In Russ.)
Arseneault L. [et al] Marijuana and madness [ed. by D. Castle, R. Murray]. Cambridge, University Press, 2004, 218 p.
Ashton H. [et al.]. Cannabis – suicide, schizophrenia and other ill-effects. Australia, Drug Free Australia Ltd, 2009, 47 p.
Vidal C. N. [et al.] Dynamically spreading frontal and cingulate deficits mapped in adolescents with schizophrenia. Archives of general psychiatry, 2006, no. 63, pp. 25-34.
Rais M. [et al.] Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. American journal of psychiatry, 2008, no. 165, pp. 490-496.
Sewell R. A. [et al.] Cannabinoids and psychosis. International review of psychiatry, 2009, no. 2, pp. 152-162.
Eggan S. M. [et al.] Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Archives of general psychiatry, 2008, no. 7, pp. 772-784.
Desfosses J. [et al.] Endocannabinoids and schizophrenia. Pharmaceuticals, 2010, no. 3, pp. 3101-3126.
Wong D. F. [et al.] Quantification of cerebral cannabinoid receptors subtype 1 (cb1) in healthy subjects and schizophrenia by the novel pet radioligand [(11)c]omar. Neuroimage, 2010, no. 52, pp. 1505-1513.
Jenko K. J. [et al.] Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia. Schizophrenia research, 2012, no. 2-3, pp. 185-188.
Defekt mozga, svyazannyy s upotrebleniem kannabisa u patsientov s shizofreniey [The defect of the brain associated with cannabis use in patients with schizophrenia]. Narkologiya, 2007, no. 4, p. 74. (In Russ.)
Szeszko P. R. [et al.] Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. British Journal of Psychiatry, 2007, no. 190, pp. 230-236.
Rukovodstvo po narkologii. V 2 t. T. 1. [pod red. I. I. Ivantsa] [Guide to Addiction. In 2 t. T. 1. [ed. I. I. Ivanets]]. Moscow, Medpraktika Publ., 2002, 444 p. (In Russ.)
Simon A. E. [et al.]The Bruderholz Study: A prospective pilot study of patients at-risk for schizophrenia in North Western Switzerland. European psychiatry, 2004, no. 19, pp. 8-9.
Giuffrida A. [et al.] Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology, 2004, no. 29, pp. 2108-2114.
Marchi N. D. [et al.] Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids in health and disease, 2003, no. 2, pp. 5.
Roser P. [et al.] Potential antipsychotic properties of central cannabinoid (cb1) receptor antagonists. World journal of biological psychiatry, 2010, no. 11, pp. 208-219.
Desfosses J. [et al.] Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the «Mirror effect» of schizophrenia. Frontiers in psychiatry, 2012, no. 3, pp. 85.
Pogosov A. Gashishnaya narkomaniya [Cannabism]. Russkiy narodnyy server protiv narkotikov Available at: http://www.narcom.ru/publ/info/259 (28.10.2013). (In Russ.)
Lazur’evskiy G. V., Nikolaeva L. A. Kannabinoidy (narkoticheskie veshchestva konopli) [Cannabinoids (cannabis drugs)]. Chisinau, Shtiintsa Publ., 1972, 69 p. (In Russ.)
Tiwari A. K. [et al.] A common polymorphism in the cannabinoid receptor 1 (cnr1) gene is associated with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology, 2010, no. 35, pp. 1315-1324.
Ho B. C. [et al.] Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophrenia research, 2011, no. 1-3, pp. 66-75.
Tong D. [et al.] Association of single-nucleotide polymorphisms in the Cannabinoid Receptor 2 gene with schizophrenia in the Han Chinese population. Journal of molecular neuroscience, 2013, no. 2, pp. 454-460.
D`Souza D. C. [et al.]Delta-9-terahydrocannabinol effects in schizophrenia: implications for cognition, psychosis and addiction. Biological psychiatry, 2005, no. 57, pp. 594-608.
Schneider M., Koch M. Chronic pubertal, but not adult chtonic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology, 2003, no. 28, pp. 1760-1769.
Smesny S. [et al.] Cannabinoids influence lipid-arachidonic acid pathways in schizophrenia. Neuropsychpharmacology, 2007, no. 32, pp. 2067-2073.
Ujike H., Morita Y. New perspectives in the studies on endocanabinoid and cannabis: cannabinoid receptors and schizophrenia. J. pharmacol sci., 2004, no. 96, pp. 376-81.
Bailey E. L., Swallow B. L. The relationship between cannabis use and schizotypal symptoms. European Psychiatry, 2004, no. 19, pp. 113-114.
Schiffman J [et al.] Symptoms of schizotypy precede cannabis use. Psychiatry Research, 2005, no. 134, pp. 37-42.
Miettunen J. [et al.] Association of cannabis use with prodromal symptoms of psychosis in adolescence. British Journal of Psychiatry, 2008, no. 192, pp. 470-471.
Romanenko R. N. [i dr.] Dinamika rasprostranennosti addiktivnogo povedeniya kak strategii sovladaniya s distressom, obuslovlennym negativnoy simptomatikoy, v prodrome pervichnogo epizoda shizofrenii [The dynamics of the prevalence of addictive behavior as a strategy of coping with the distress caused by negative symptoms in schizophrenia prodrome primary episode]. Prikladnye informatsionnye aspekty meditsiny, 2008, no. 11, 162-166. (In Russ.)
Mauri M. [et al.] Substance abuse in first-episode schizophrenic patients: a retrospective study. Clinical practice and epidemiology in mental health, 2006, no. 2, pp. 1-8.
Megrabyan A. A. [et al.] Rol’ gashishnoy intoksikatsii v klinicheskoy kartine shizofrenii [Role of hashish intoxication in the clinical picture of schizophrenia]. Alkogolizm i nekotorye drugie intoksikatsionnye zabolevaniya nervnoy sistemy i psikhicheskoy sfery. Materialy plenuma Vsesoyuznogo meditsinskogo obshchestva nevropatologov i psikhiatrov, 1972, pp. 99-102. (In Russ.)
Petrov R. V., Borisova L. F. Psikhicheskie rasstroystva i zavisimost’ [Mental disorders and dependency]. Novosti nauki i tekhniki, 2006, no. 9, pp. 18-20. (In Russ.)
Solowij N. [et al.] Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? Journal of psychiatry & neuroscience, 2007, no. 1, pp. 32-50.
Pyatnitskaya I. N. Obshchaya i chastnaya narko-logiya: rukovodstvo dlya vrachey [General and private drug and alcohol abuse: a guide for doctors]. Moscow, Medicine Publ., 2008, 640 p. (In Russ.)
Lichko A. E., Bitenskiy V. S. Podrostkovaya narkologiya [Teenage Drug Addiction]. Leningrad, Medicine Publ., 1991, 304 p. (In Russ.)
Korkina M. V., Lakosina N. D., Lichko A. E., Sergeev I. I. Psikhiatriya: uchebnik dlya studentov [Psychiatry: a textbook for students]. Moscow, MEDpress- info Publ., 2006, 576 p. (In Russ.)
Klimenko T. V. [et al.] Klinicheskiy patomorfoz zavisimosti ot kannabinoidov u bol’nykh shizofreniey (po dannym otdalennogo katamneza) [Clinical pathomorphosis depending on cannabinoids in patients with schizophrenia (according to remote catamnesis)]. Narkologiya, 2008, no. 1, pp. 41-45. (In Russ.)
Krishtal’ E. V. [et al.] Shizofreniya, oslozhnennaya upotrebleniem psikhoaktivnykh veshchestv, v sudebno-psikhiatricheskoy praktike [Schizophrenia is complicated by the use of psychoactive substances in forensic psychiatric practice]. Arhiv psyhiatrii’, 2008, no. 4, p. 56. (In Russ.)
Macleod J. Cannabis use and psychosis: the origins and implications of an association. Advances in psychiatric treatment, 2007, no. 13, pp. 400-411.
Maki P. [et al.] Predictors of schizophrenia – a review. British medical bulletin, 2005, no. 73-74, pp. 1-15.
Авторське право (c) 2016 П. В. Кидонь
Цю роботу ліцензовано за Міжнародня ліцензія Creative Commons Attribution 4.0.
